Abstract
In the last few years has been reported that agonists of G-protein coupled receptors (GPCRs) are capable of promoting a preferential activation profile or biased to a particular intracellular signaling pathway. This phenomenon has received different names in the literature, such as collateral efficacy, pluridimensional efficacy, functional selectivity or biased agonism. In general, this p…